Castle Biosciences Inc Revenue Growth Rates (CSTL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Castle Biosciences Inc   (NASDAQ: CSTL)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

CSTL's Revenue Growth by Quarter and Year

Castle Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CSTL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 103.55
1st Quarter March 83.68
FY 187.23

CSTLs Annual Revenue
Castle Biosciences Inc 's Revenue in the fiscal year 2025 $ 344.23 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2024 $ 332.07 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2023 $ 219.79 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2022 $ 137.04 millions
Castle Biosciences Inc 's Revenue in the fiscal year 2021 $ 94.09 millions




CSTL Revenue second quarter 2026 Y/Y Growth Comment
Castle Biosciences Inc reported Revenue improvement of 20.14% year on year in the second quarter 2026, to $ 103.55 millions, this is lower than Castle Biosciences Inc 's recent average Revenue rise of 45.55%.

Looking into second quarter 2026 results within Medical Laboratories industry 24 other companies have achieved higher Revenue growth. While Castle Biosciences Inc ' s Revenue rise of 20.14% ranks overall at the positon no. 2640 in the second quarter 2026.


CSTL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 0.81 % 30.54 % 72.46 %
3rd Quarter September - -3.19 % 39.5 % 66.14 %
2nd Quarter June 20.14 % -0.93 % 73.51 % 43.92 %
1st Quarter March -4.9 % 20.58 % 73.57 % 56.57 %
FY   - 3.67 % 51.08 % -

Financial Statements
Castle Biosciences Inc 's second quarter 2026 Revenue $ 103.55 millions CSTL's Income Statement
Castle Biosciences Inc 's second quarter 2025 Revenue $ 86.19 millions Quarterly CSTL's Income Statement


CSTL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 4.78 % 0.62 % 7.53 %
3rd Quarter September - -3.65 % -1.4 % 22.64 %
2nd Quarter June 23.74 % -2.05 % 19.23 % 19.27 %
1st Quarter March -3.83 % 1.95 % 10.36 % 9.65 %
FY (Year on Year)   - 3.67 % 51.08 % -


Back to CSTL Growth rate Comparisons >> Back to CSTL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #25
Healthcare Sector #379
Overall #2640

Revenue Y/Y Growth Statistics
High Average Low
127.62 % 45.55 % -2.06 %
(Dec 31 2019)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #25
Healthcare Sector #379
Overall #2640
Revenue Y/Y Growth Statistics
High Average Low
127.62 % 45.55 % -2.06 %
(Dec 31 2019)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Castle Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
208.08 % 14.2 % -27 %
(Dec 31 2018)  


CSTL's II. Quarter Q/Q Revenue Comment
Castle Biosciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.74%, to $ 103.55 millions, from $83.68 millions in the first quarter.
CSTL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Castle Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 447.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #95
Overall #447
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #4
Healthcare Sector #95
Overall #447
Revenue Q/Q Growth Statistics
High Average Low
208.08 % 14.2 % -27 %
(Dec 31 2018)  


CSTL's II. Quarter Q/Q Revenue Comment
Castle Biosciences Inc achieved in the II. Quarter 2026 above company average sequential Revenue jump of 23.74%, to $ 103.55 millions, from $83.68 millions in the first quarter.
CSTL is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 3 other companies have achieved higher Revenue quarter on quarter growth. While Castle Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 447.


Castle Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 357.28 $ 339.92 $ 344.23 $ 343.53 $ 346.27
Y / Y Revenue Growth (TTM) 3.18 % -2.06 % 3.66 % 10.15 % 20.4 %
Year on Year Revenue Growth Overall Ranking # 851 # 341 # 110 # 83 # 37
Seqeuential Revenue Change (TTM) 5.11 % -1.25 % 0.2 % -0.79 % -0.23 %
Seq. Revenue Growth (TTM) Overall Ranking # 2655 # 1790 # 1026 # 1198 # 209


Cumulative Revenue growth Comment
Although Castle Biosciences Inc 's Annual Revenue growth year on year were below company's average 45.55% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.18% year on year, from -2.06% in Mar 31 2026.

In the Healthcare sector 174 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 341 to 851.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 175
Overall # 851

Revenue TTM Y/Y Growth Statistics
High Average Low
127.62 %
 45.55 %
-2.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 379
S&P 500 # 2655
Cumulative Revenue growth Comment
Although Castle Biosciences Inc 's Annual Revenue growth year on year were below company's average 45.55% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 3.18% year on year, from -2.06% in Mar 31 2026.

In the Healthcare sector 174 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 341 to 851.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 25
Healthcare Sector # 175
Overall # 851

Revenue TTM Y/Y Growth Statistics
High Average Low
127.62 %
45.55 %
-2.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 25
Sector # 379
S&P 500 # 2655




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CSTL's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions
Lightwave Logic Inc 27.91%$ 27.909 millions
American Shared Hospital Services27.15%$ 27.149 millions
Protalix Biotherapeutics inc 27.07%$ 27.066 millions
Alkermes Plc 26.97%$ 26.968 millions
Lucid Diagnostics Inc 26.74%$ 26.741 millions
Lifestance Health Group Inc 26.08%$ 26.076 millions
Ani Pharmaceuticals Inc25.87%$ 25.866 millions


About Castle Biosciences Inc Revenue Growth Rates (CSTL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Castle Biosciences Inc (CIK 1447362).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-051052
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Castle Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.